Home › Research › Getting a diagnosis
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease
Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P.. Alzheimer's research & therapy, 2019-04-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42 ), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181 ) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ 42 to Aβ 40 (Aβ 42/40 Ratio) has been suggested to be superior to the concentration of Aβ 42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ 42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ 42/40 ratio, rather than the absolute value of CSF Aβ 42 , should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.
What this study adds
Evidence grade: Low
This is a narrative review. This review concludes that the cerebrospinal fluid Aβ42/40 ratio, rather than the absolute value of Aβ42, should be used when analysing CSF Alzheimer's disease biomarkers to improve the percentage of appropriately diagnosed patients. It concerns improving diagnostic accuracy and distinguishing Alzheimer's disease from other dementias, not treating, curing or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019). Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-019-0485-0
Vancouver
Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimer's research & therapy. 2019. doi:10.1186/s13195-019-0485-0. PMID: 31010420.
BibTeX
@article{hansson2019-31010420,
author = {Hansson, O. and Lehmann, S. and Otto, M. and Zetterberg, H. and Lewczuk, P.},
title = {{Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease}},
journal = {Alzheimer's research \& therapy},
year = {2019},
doi = {10.1186/s13195-019-0485-0},
pmid = {31010420},
url = {https://doi.org/10.1186/s13195-019-0485-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42 ), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181 ) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD).
- In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD).
- The concentration ratio of Aβ 42 to Aβ 40 (Aβ 42/40 Ratio) has been suggested to be superior to the concentration of Aβ 42 alone when identifying patients with AD.
- This article reviews the available evidence on the use of the CSF Aβ 42/40 ratio in the diagnosis of AD.
- Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ 42/40 ratio, rather than the absolute value of CSF Aβ 42 , should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.
Why it matters
This review concludes that the cerebrospinal fluid Aβ42/40 ratio, rather than the absolute value of Aβ42, should be used when analysing CSF Alzheimer's disease biomarkers to improve the percentage of appropriately diagnosed patients. It concerns improving diagnostic accuracy and distinguishing Alzheimer's disease from other dementias, not treating, curing or preventing the disease.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 57/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 587 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 65.2 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 5 / 6 | Cited 39.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 38 other studies in this library |
| Still being cited | 4 / 4 | Cited 248 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Piotr Lewczuk: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31010420) |
| Free to read | 2 / 2 | Free to read |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-019-0485-0
- PubMed: 31010420
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
38 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.